A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease

This study is a prospective, randomized, controlled study, follow the principle of PICOST design, specific as follows: Participants (the list) : preliminary clinical diagnosis of coronary atherosclerotic heart disease, heart failure. Intervention (Intervention) : conventional drug therapy + new cardiac rehabilitation therapy, a new cardiac rehabilitation treatment reference guide requirements, according to the actual circumstance of patients treated with 1-3 months Intervention. Comparator(control): conventional drug therapy + traditional cardiac rehabilitation therapy. The traditional cardiac rehabilitation therapy referred to domestic and international guidelines and consensus, and used 1 week-3 months of treatment intervention according to the actual situation of patients. Outcome (the end) : the primary end point: D_SPECT examination, were followed up for 6 months to evaluate myocardial perfusion imaging is reduce ischemic area. The secondary end point: 1) the blood biochemical examination and myocardial necrosis markers, etc.; 2) the cardiopulmonary exercise testing: maximum kilograms oxygen uptake and anaerobic threshold when the maximum kilograms oxygen uptake; 3) the major adverse cardiovascular events: cardioascular death, non-fatal myocardial infarction, unplanned coronary artery reconstruction, stroke, heart failure and angina associated hospitalized again; 4) patients family rehabilitation treatment adherence

Inclusion criteria

• Aged between 18 and 85 years old
• Female subjects no pregnancy
• The main admission diagnosis of ischemic heart disease (coronary heart disease, myocardial infarction, ischemic heart failure, etc.)
• The need for cardiac rehabilitation treatment

Exclusion criteria

• acute respiratory distress syndrome (ARDS);
• acute episode of COPD;
• uncontrolled pulmonary infection;
• acute heart failure; acute pulmonary embolism;
• acute myocarditis/pericarditis;
• severe arrhythmia (degree II or III atrioventricular block, atrial flutter, or atrial fibrillation);
• sternotomy, rib fracture, thoracic deformity, or other neurological diseases that may affect respiratory muscles